Steering Committee
Our Steering Committee is formed by professionals endowed with very deep experience in life sciences, acquired within pharma, biotech and service companies.
The Steering Committee is encharged of the development strategy for the ongoing projects and of the relationship with partners, consultants and service companies collaborating with Rare Partners.
Germano Carganico, Chairman of the Steering Committee
Marco Prosdocimi, Managing Director
Germano Carganico
Germano, graduated in Chemistry from Milan University in 1977, has a very long experience in R&D, regulatory affairs and company management, gained in pharmaceutical and biotech companies, such as Farmitalia Carlo Erba, Menarini, Axxam and MolMed.
He successfully managed the international registration of several new pharmaceutical products and has been founding partner of two leading consulting companies in the field of life sciences, namely Pharma Quality Europe and Regulatory Pharma Net.
Germano served as General Manager of Toscana Life Sciences foundation from 2005 to 2010 and has taught Business Development at the University of Siena in the same years. From 2011 to 2017 he worked for MolMed, where he held for five years the position of General Manager, R&D and Operations, and more recently that of Executive Director, Strategic Affairs.
Since August 2017 he is full time dedicated to Rare Partners, where is founding Partner and Chairman of the Steering Committee.
Marco Prosdocimi
Marco is Managing Director of Rare Partners since its foundation in March 2010. He collaborates as a consultant with Pharmaceutical Companies, with Investment Funds and with Research Organizations since 1996, focusing his activity in the areas of Research & Development.
Prior to this he rose to Research & Development Director at Fidia Research Laboratories during a 15-year career (1981-1996) with the company. Marco has more than 35 years of experience in R&D, gained in Academic Institutions (University of Padova and Thomas Jefferson University) and in companies, including CM&D Pharma, PharmEste and Angelini Ricerche.
He has been member of the scientific board of several biotech companies and collaborates with public and private institutions for the review of scientific projects and business plans. Marco is author of more than 120 papers, 200 abstracts and several patents, on cardiovascular and autonomic pharmacology, both at preclinical and clinical level.
Marco holds a degree in Pharmacy from the University of Padova.
Paolo Baroldi
Paolo Baroldi, MD, PhD, currently is Chief Medical Officer (CMO) of Bloomscience, a biotech company focused on microbiome (San Diego, CA). From 2006 to 2009, and from 2013 to 2017, served as Senior Vice President and Chief Medical Officer at Vanda Pharmaceuticals. (Washington, DC).
In 2012-13, he was CEO of Galileo Research (Pisa), a spin-off biotech company of Abiogen Holding, focused on ovarian cancer immunotherapy.
From 2003 to 2006, Paolo served as Vice President of Corporate Drug development and Chairman of the R&D Board at Chiesi Farmaceutici SpA. From 1998 to 2002 he was Global Head of Clinical Pharmacology at Novartis Pharma, responsible for all early development studies across eight different therapeutic areas.
Paolo holds degrees in Medicine and Surgery (Universitas Studiorum Milan), Philosophy and History (Universitas Studiorum Milan), a PhD in Clinical Pharmacology (Universitas Studiorum Milan) and an Executive MBA from Harvard University.
Paolo held a contract professor position at Johns Hopkins University until 2014.
Fabio Borella
Fabio is co-founder and President of Neupharma, a pharmaceutical company focusing on rare diseases, in particular in cystic fibrosis. Fabio is also President of Almira Pharma, where he leads the development program of a promising drug for the cure of interstitial cystitis, and he is Member of the Board of Plumestar, a spin off company from Parma University, focused on the devolopment of inhalatory formulations.
Previously Fabio held managing positions in several pharmaceutical companies. From 1999 to 2011 he started and developed the “rare diseases” business area in Dompé Farmaceutici, from 1992 to 1999 he has been Scientific Director of Istituto Biochimico Italiano, from 1988 to 1992 Director od Research & Development in Medidom SA, company located in Geneva.
Fabio holds a degree in Chemistry and Pharmaceutical Technologies from the University of Milan.
Fabrizio Minoja
Fabrizio is partner at Bianchetti Bracco Minoja (BBM), a patent attorney’s firm representing national and international companies and research institutes, active in the pharmaceutical and biotechnological field. He qualified as European Patent Attorney in 1986.
Fabrizio has been appointed official expert of the Court of Milan and Turin in validity and infringement proceedings and has lectured at the University of Milan and at the Basic European Patent Law courses, Centre d'Etudes Internationales de la Propriété Industrielle (CEIPI), Robert Schumann University, in Strasburg.
Fabrizio graduated in Chemistry at the University of Milan.